Sunday, September 15, 2013

Glivec

Introduction The Novartis case can be traced to 1997 when a letters overt industry was filed by Novartis AG for the ?- microcrystalline of imatinib mesylate (brand name Glivec) which was a slightly several(predicate) version of their 1993 indubitable, a vital anti-leukaemia drug, filed in the Chennai (Madras) unornamented fleck. The prayer claimed that they had invented the beta crystalline salt from the free abode of imatinib. In 2003, Glivec was granted EMR in the Indian market. Novartis obtained pronounces preventing some of the generic wine manufacturers from producing the generic equivalents of Glivec in India. Soon, Novartis was change Gleevec at USD 2666 per patient of per year.15 Generic companies had been selling their generic versions at USD 177 to 266 per patient per month. Pre-grant oppositions were filed by Natco Pharma Ltd., M/s Cipla Ltd., M/s Hetro Drugs Ltd., M/s crab louse Patient Aid tie-in and M/s Ranbaxy Laboratories Ltd., India and in an order dat ed January 25, 2006, the accomplice Controller of Patents and Designs, Chennai Patent Office rejected the Novartis industriousness. History of Glivec in India 1993: The base compound of Glivec, imatinib, is invented and procure worldwide. There is no patent filed in India at this time, as India does not have patent laws for pharmaceutic products.
bestessaycheap.com is a professional essay writing service at which you can buy essays on any topics and disciplines! All custom essays are written by professional writers!
1995: India joins the World contend Organization (WTO) and begins its mandated 10-year transition period to bring its patent laws into coalition with TRIPS. JULY 1998: Novartis files a mailbox application in India for imatinib mesylate in crystalline form, the active ingredient of Glivec , in accordance with Indias victual for obta! ining patents. DECEMBER 2001: Novartis obtains marketing cheering for Glivec in India. APRIL 2002: Glivec is launched in India. folk 2002: Novartis launches the Glivec International Patient aid Program (GIPAP) in India. NOVEMBER 2003: Novartis is awarded scoop Marketing Rights (EMR) for Glivec, marking the commencement exercise time a pharmaceutical firm is...If you want to deject a full essay, order it on our website: BestEssayCheap.com

If you want to get a full essay, visit our page: cheap essay

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.